The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis

Background Lung cancer is the leading cause of cancer‐related deaths worldwide and the prognosis remains poor. The recent introduction of the immune checkpoint inhibitor (ICI), or plus chemotherapy, both resulted in the survival benefit for patients with advanced non‐small‐cell lung cancer (NSCLC),...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of cellular physiology 2020-05, Vol.235 (5), p.4913-4927
Hauptverfasser:	Wang, Chengdi, Qiao, Wenliang, Jiang, Yuting, Zhu, Min, Shao, Jun, Wang, Tao, Liu, Dan, Li, Weimin
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Apoptosis B7-H1 Antigen - antagonists & inhibitors Biomarkers Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - immunology Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Cell death Chemotherapy Clinical trials efficacy Heterogeneity Humans immune checkpoint inhibitor Immune checkpoint inhibitors Immune Checkpoint Inhibitors - adverse effects Immune Checkpoint Inhibitors - therapeutic use Immunotherapy Immunotherapy - adverse effects Inhibitors Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - immunology Lung Neoplasms - mortality Lung Neoplasms - pathology Medical prognosis Meta-analysis Monoclonal antibodies Non-small cell lung carcinoma non‐small‐cell lung cancer Original Original s Patients PD-1 protein PD-L1 protein Pembrolizumab Platinum Progression-Free Survival Randomized Controlled Trials as Topic safety Survival Targeted cancer therapy Time Factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!